nodes	percent_of_prediction	percent_of_DWPC	metapath
Brinzolamide—CA9—cervical cancer	0.874	1	CbGaD
Brinzolamide—CA14—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00994	0.122	CbGpPWpGaD
Brinzolamide—CA6—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00969	0.118	CbGpPWpGaD
Brinzolamide—CA5A—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00969	0.118	CbGpPWpGaD
Brinzolamide—CA7—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00905	0.111	CbGpPWpGaD
Brinzolamide—CA5B—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00905	0.111	CbGpPWpGaD
Brinzolamide—CA12—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00838	0.102	CbGpPWpGaD
Brinzolamide—Dorzolamide—CA9—cervical cancer	0.00778	1	CrCbGaD
Brinzolamide—CA4—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00668	0.0817	CbGpPWpGaD
Brinzolamide—CA2—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00641	0.0784	CbGpPWpGaD
Brinzolamide—CA1—Reversible hydration of carbon dioxide—CA9—cervical cancer	0.00614	0.0751	CbGpPWpGaD
Brinzolamide—CA6—exocrine gland—cervical cancer	0.00598	0.171	CbGeAlD
Brinzolamide—CA5A—female reproductive system—cervical cancer	0.003	0.0858	CbGeAlD
Brinzolamide—CA7—renal system—cervical cancer	0.00249	0.0713	CbGeAlD
Brinzolamide—CA1—C-MYB transcription factor network—PIAS3—cervical cancer	0.0021	0.0256	CbGpPWpGaD
Brinzolamide—CA2—exocrine gland—cervical cancer	0.00206	0.0589	CbGeAlD
Brinzolamide—CA9—female reproductive system—cervical cancer	0.00175	0.0502	CbGeAlD
Brinzolamide—CA12—renal system—cervical cancer	0.00162	0.0463	CbGeAlD
Brinzolamide—CA5B—mammalian vulva—cervical cancer	0.00136	0.0389	CbGeAlD
Brinzolamide—CA12—female reproductive system—cervical cancer	0.0013	0.0371	CbGeAlD
Brinzolamide—CA1—renal system—cervical cancer	0.00128	0.0367	CbGeAlD
Brinzolamide—CA5B—female reproductive system—cervical cancer	0.00116	0.0333	CbGeAlD
Brinzolamide—CA5B—vagina—cervical cancer	0.00105	0.0301	CbGeAlD
Brinzolamide—CA1—female reproductive system—cervical cancer	0.00103	0.0294	CbGeAlD
Brinzolamide—CA4—renal system—cervical cancer	0.001	0.0287	CbGeAlD
Brinzolamide—CA2—epithelium—cervical cancer	0.000895	0.0256	CbGeAlD
Brinzolamide—CA2—decidua—cervical cancer	0.000846	0.0242	CbGeAlD
Brinzolamide—CA2—renal system—cervical cancer	0.00083	0.0238	CbGeAlD
Brinzolamide—CA4—female reproductive system—cervical cancer	0.000802	0.023	CbGeAlD
Brinzolamide—CA2—mammalian vulva—cervical cancer	0.000776	0.0222	CbGeAlD
Brinzolamide—CA4—female gonad—cervical cancer	0.00073	0.0209	CbGeAlD
Brinzolamide—CA5B—lymph node—cervical cancer	0.00068	0.0195	CbGeAlD
Brinzolamide—CA2—female reproductive system—cervical cancer	0.000665	0.019	CbGeAlD
Brinzolamide—CA2—female gonad—cervical cancer	0.000605	0.0173	CbGeAlD
Brinzolamide—CA2—vagina—cervical cancer	0.000601	0.0172	CbGeAlD
Brinzolamide—CA1—lymph node—cervical cancer	0.0006	0.0172	CbGeAlD
Brinzolamide—CA1—C-MYB transcription factor network—HES1—cervical cancer	0.000598	0.00731	CbGpPWpGaD
Brinzolamide—CA9—HIF-1-alpha transcription factor network—TERT—cervical cancer	0.000559	0.00683	CbGpPWpGaD
Brinzolamide—CYP3A4—renal system—cervical cancer	0.000536	0.0153	CbGeAlD
Brinzolamide—CA4—lymph node—cervical cancer	0.000469	0.0134	CbGeAlD
Brinzolamide—CYP3A4—female reproductive system—cervical cancer	0.000429	0.0123	CbGeAlD
Brinzolamide—CA2—lymph node—cervical cancer	0.000389	0.0111	CbGeAlD
Brinzolamide—CA1—C-MYB transcription factor network—CD4—cervical cancer	0.000338	0.00413	CbGpPWpGaD
Brinzolamide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000336	0.00411	CbGpPWpGaD
Brinzolamide—CYP3A4—Tryptophan metabolism—UBE3A—cervical cancer	0.000324	0.00396	CbGpPWpGaD
Brinzolamide—CA14—Metabolism—CA9—cervical cancer	0.000202	0.00247	CbGpPWpGaD
Brinzolamide—CA6—Metabolism—CA9—cervical cancer	0.000197	0.00241	CbGpPWpGaD
Brinzolamide—CA5A—Metabolism—CA9—cervical cancer	0.000197	0.00241	CbGpPWpGaD
Brinzolamide—CA5B—Metabolism—CA9—cervical cancer	0.000184	0.00225	CbGpPWpGaD
Brinzolamide—CA7—Metabolism—CA9—cervical cancer	0.000184	0.00225	CbGpPWpGaD
Brinzolamide—CA12—Metabolism—CA9—cervical cancer	0.00017	0.00208	CbGpPWpGaD
Brinzolamide—CA4—Metabolism—CA9—cervical cancer	0.000136	0.00166	CbGpPWpGaD
Brinzolamide—CA2—Metabolism—CA9—cervical cancer	0.00013	0.00159	CbGpPWpGaD
Brinzolamide—CA1—Metabolism—CA9—cervical cancer	0.000125	0.00153	CbGpPWpGaD
Brinzolamide—CA9—Cellular responses to stress—MTOR—cervical cancer	0.000119	0.00146	CbGpPWpGaD
Brinzolamide—Rash maculo-papular—Topotecan—cervical cancer	9.3e-05	0.0528	CcSEcCtD
Brinzolamide—CA9—Cellular responses to stress—STAT3—cervical cancer	9.2e-05	0.00112	CbGpPWpGaD
Brinzolamide—CA14—Metabolism—MTHFR—cervical cancer	8.2e-05	0.001	CbGpPWpGaD
Brinzolamide—CA5A—Metabolism—MTHFR—cervical cancer	7.99e-05	0.000977	CbGpPWpGaD
Brinzolamide—CA6—Metabolism—MTHFR—cervical cancer	7.99e-05	0.000977	CbGpPWpGaD
Brinzolamide—CA7—Metabolism—MTHFR—cervical cancer	7.46e-05	0.000912	CbGpPWpGaD
Brinzolamide—CA5B—Metabolism—MTHFR—cervical cancer	7.46e-05	0.000912	CbGpPWpGaD
Brinzolamide—CA9—Cellular responses to stress—TP53—cervical cancer	7.02e-05	0.000858	CbGpPWpGaD
Brinzolamide—CA12—Metabolism—MTHFR—cervical cancer	6.91e-05	0.000845	CbGpPWpGaD
Brinzolamide—Infestation NOS—Topotecan—cervical cancer	5.72e-05	0.0325	CcSEcCtD
Brinzolamide—Infestation—Topotecan—cervical cancer	5.72e-05	0.0325	CcSEcCtD
Brinzolamide—CA4—Metabolism—MTHFR—cervical cancer	5.51e-05	0.000674	CbGpPWpGaD
Brinzolamide—Hepatobiliary disease—Topotecan—cervical cancer	5.41e-05	0.0307	CcSEcCtD
Brinzolamide—Epistaxis—Topotecan—cervical cancer	5.4e-05	0.0307	CcSEcCtD
Brinzolamide—CA2—Metabolism—MTHFR—cervical cancer	5.28e-05	0.000646	CbGpPWpGaD
Brinzolamide—Rhinitis—Topotecan—cervical cancer	5.15e-05	0.0293	CcSEcCtD
Brinzolamide—Hypoaesthesia—Topotecan—cervical cancer	5.11e-05	0.029	CcSEcCtD
Brinzolamide—Pharyngitis—Topotecan—cervical cancer	5.1e-05	0.029	CcSEcCtD
Brinzolamide—CA1—Metabolism—MTHFR—cervical cancer	5.07e-05	0.000619	CbGpPWpGaD
Brinzolamide—Angiopathy—Topotecan—cervical cancer	4.66e-05	0.0265	CcSEcCtD
Brinzolamide—Immune system disorder—Topotecan—cervical cancer	4.64e-05	0.0264	CcSEcCtD
Brinzolamide—Mediastinal disorder—Topotecan—cervical cancer	4.63e-05	0.0263	CcSEcCtD
Brinzolamide—Alopecia—Topotecan—cervical cancer	4.54e-05	0.0258	CcSEcCtD
Brinzolamide—Malnutrition—Topotecan—cervical cancer	4.47e-05	0.0254	CcSEcCtD
Brinzolamide—CA9—Metabolism—MTHFR—cervical cancer	4.45e-05	0.000545	CbGpPWpGaD
Brinzolamide—Back pain—Topotecan—cervical cancer	4.33e-05	0.0246	CcSEcCtD
Brinzolamide—Muscle spasms—Topotecan—cervical cancer	4.3e-05	0.0244	CcSEcCtD
Brinzolamide—Ill-defined disorder—Topotecan—cervical cancer	4.15e-05	0.0236	CcSEcCtD
Brinzolamide—Malaise—Topotecan—cervical cancer	4.03e-05	0.0229	CcSEcCtD
Brinzolamide—Cough—Topotecan—cervical cancer	3.9e-05	0.0222	CcSEcCtD
Brinzolamide—Arthralgia—Topotecan—cervical cancer	3.81e-05	0.0216	CcSEcCtD
Brinzolamide—Chest pain—Topotecan—cervical cancer	3.81e-05	0.0216	CcSEcCtD
Brinzolamide—Myalgia—Topotecan—cervical cancer	3.81e-05	0.0216	CcSEcCtD
Brinzolamide—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	3.78e-05	0.0215	CcSEcCtD
Brinzolamide—Discomfort—Topotecan—cervical cancer	3.76e-05	0.0214	CcSEcCtD
Brinzolamide—Infection—Topotecan—cervical cancer	3.63e-05	0.0206	CcSEcCtD
Brinzolamide—Nervous system disorder—Topotecan—cervical cancer	3.58e-05	0.0203	CcSEcCtD
Brinzolamide—Skin disorder—Topotecan—cervical cancer	3.55e-05	0.0201	CcSEcCtD
Brinzolamide—Musculoskeletal discomfort—Topotecan—cervical cancer	3.33e-05	0.0189	CcSEcCtD
Brinzolamide—Paraesthesia—Topotecan—cervical cancer	3.28e-05	0.0186	CcSEcCtD
Brinzolamide—Dyspnoea—Topotecan—cervical cancer	3.26e-05	0.0185	CcSEcCtD
Brinzolamide—Dyspepsia—Topotecan—cervical cancer	3.21e-05	0.0183	CcSEcCtD
Brinzolamide—Decreased appetite—Topotecan—cervical cancer	3.17e-05	0.018	CcSEcCtD
Brinzolamide—Gastrointestinal disorder—Topotecan—cervical cancer	3.15e-05	0.0179	CcSEcCtD
Brinzolamide—Fatigue—Topotecan—cervical cancer	3.15e-05	0.0179	CcSEcCtD
Brinzolamide—Pain—Topotecan—cervical cancer	3.12e-05	0.0177	CcSEcCtD
Brinzolamide—Feeling abnormal—Topotecan—cervical cancer	3.01e-05	0.0171	CcSEcCtD
Brinzolamide—Urticaria—Topotecan—cervical cancer	2.9e-05	0.0165	CcSEcCtD
Brinzolamide—Hypersensitivity—Topotecan—cervical cancer	2.69e-05	0.0153	CcSEcCtD
Brinzolamide—Asthenia—Topotecan—cervical cancer	2.62e-05	0.0149	CcSEcCtD
Brinzolamide—Pruritus—Topotecan—cervical cancer	2.58e-05	0.0147	CcSEcCtD
Brinzolamide—Diarrhoea—Topotecan—cervical cancer	2.5e-05	0.0142	CcSEcCtD
Brinzolamide—Dizziness—Topotecan—cervical cancer	2.41e-05	0.0137	CcSEcCtD
Brinzolamide—Vomiting—Topotecan—cervical cancer	2.32e-05	0.0132	CcSEcCtD
Brinzolamide—Rash—Topotecan—cervical cancer	2.3e-05	0.0131	CcSEcCtD
Brinzolamide—Dermatitis—Topotecan—cervical cancer	2.3e-05	0.0131	CcSEcCtD
Brinzolamide—Headache—Topotecan—cervical cancer	2.29e-05	0.013	CcSEcCtD
Brinzolamide—Nausea—Topotecan—cervical cancer	2.17e-05	0.0123	CcSEcCtD
Brinzolamide—CYP3A4—Metabolism—CA9—cervical cancer	1.85e-05	0.000226	CbGpPWpGaD
Brinzolamide—CYP3A4—Metabolism—MTHFR—cervical cancer	7.5e-06	9.17e-05	CbGpPWpGaD
